TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06801314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise using cycle ergometer in addition to usual care
Description: aerobic exercise group):Patients in this group will be received usual care and cycle ergometer aerobic exercise Mood of exercise: continuous aerobic exercise~* Modality of exercise: cycle ergometer~* Intensity of exercise: low to moderate intensity and HR (calculated as recommended by the American College of Sports Medicine (ACSM) and tolerated up to 20-30 bpm above the resting HR), BP, SpO2 and rate of perceived exertion through the Borg Scale (10-13) will be monitor during cycling~* Duration: 15-20 min including 5 min warm up and 5 min cool down and working phase from 5-10 min~* Frequency: daily until discharge aerobic exercise group guided by wearable artificial intelligence ECG monitor to real-time support, guide and stop exercise when there is any adverse events will occur.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resisted exercise using weights and dumbbells in addition to usual care
Description: resisted exercise group): Patients in this group will be received usual care and resisted exercise~* Mode: resisted exercise~* Modality: dumbbells or sand bags tied around main groups of muscles for upper and lower limbs Intensity of exercise: the load that the patient can lift for 10-12 repetition at RPE of 10-13 and 1-2 sets resisted exercise group guided by wearable artificial intelligence ECG monitor to real-time support, guided and stop exercise when there is any adverse events will occur.
Study: NCT05320874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KM257 Bispecific antibody
Description: Part 1a dose escalation:~There will be 3 increasing dose levels (3mg/kg,6mg/kg,12mg/kg). Patients will be intravenously administrated with one dose of KM257, QW for continuous cycles of 21 consecutive days for each cycle. The dosing interval may be adjusted during the study based on emerging data from this trial.~Part 1b dose expansion:~Part1b:For cohort 1 and cohort2, KM257 will be given at the RP2D identified in Part1a;~For cohort 3 to 7:KM257 will be given combined with one of the following selected drug combination:~Drug: Capecitabine Combination therapy with KM257 - Cohort 3~Drug: Paclitaxel or Docetaxel or Irinotecan Combination therapy with KM257 - Cohort 4~Drug: Gemcitabine+Cisplatin Combination therapy with KM257 - Cohort 5~Drug: Gemcitabine+Cisplatin or Carboplatin Combination therapy with KM257 - Cohort 6~Drug:Carboplatin+Paclitaxel Combination therapy with KM257 - Cohort 7
Study: NCT05985200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3032950
Description: BI 3032950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3032950
Description: BI 3032950
Study: NCT06801314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care using mobilization and breathing exercise
Description: mobilization and breathing exercise
Study: NCT06800755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexeryl (RL3020-DP0364)
Description: Product application on body (head excluded)
Study: NCT06800950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV Control
Description: Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV Control
Description: Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV Control
Description: Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
Study: NCT06801119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HN2301 injection
Description: Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.
Study: NCT06800313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD-0915
Description: A treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Study: NCT06800924

Intervention type: OTHER
Intervention: Postural and mobility analysis
Description: Postural and mobility parameters were obtained with the use of the Idiag M360 scan tool (Idiag, Fehraltorf, Switzerland)

Intervention type: OTHER
Intervention: Postural and mobility analysis
Description: Postural and mobility parameters were obtained with the use of the Idiag M360 scan tool (Idiag, Fehraltorf, Switzerland)
Study: NCT05263037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx
Description: VR software with interactive content

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx
Description: VR software with interactive content

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR
Description: VR with neutral non-interactive content

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR
Description: VR with neutral non-interactive content
Study: NCT05985200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3032950
Description: BI 3032950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3032950
Description: BI 3032950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3032950
Description: Placebo matching BI 3032950
Study: NCT05899491

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ARMA
Description: Patients will be instructed to fast for 6 hours pre-ARMA, the Procedure will be performed under propofol-based sedation. Patients will be in the left lateral decubitus position. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: UGI Endoscopy
Description: UGI Endoscopy will be performed under propofol based sedation with scope kept inside for atleast 5 minutes.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry, reflux questionnaire.
Study: NCT04693897

Intervention type: DRUG
Intervention: Mirabegron 50 MG
Description: Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
Study: NCT05286658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEG/EEG
Description: The participant will sit still while their head is slid into the helmet-shaped bottom of the MEG device. The MEG contains sensors that passively detect weak magnetic fields outside the head produced by brain activity. The computer records the brain's electrical activity on the screen as wavy lines. The investigators will also ask you to wear sensors to capture eye-blinks (electrooculogram) and heartbeats (electrocardiogram) to facilitate removal from the MEG signal during analysis.~Participant will sit in front of a projector screen and be asked to put on a pair of headphones. Participant will be shown real words or nonsense words to read, the investigators may play sounds through headphones for the participant to repeat. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MRI
Description: An MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures of organs and structures inside the body. The participant will be able to hear and speak to the research staff at all times during the MRI procedures. The MRI test will take about 15 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speaking Tasks
Description: The participant may be asked to perform some of the tasks from MEG again, this time outside of the scanner. As before, the participant may see real words or nonsense words to read, and the investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
Study: NCT05099705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to a Family Service Navigator and Treatment Support System
Description: An RCT will be conducted. 40 participants will be randomly assigned to the intervention group and 15 participants to the non-personalized comparison group (i.e., information, training, and referral). The intervention group will have access to a navigator and the treatment support system.
Study: NCT04339933

Intervention type: DIAGNOSTIC_TEST
Intervention: FGFR test
Description: Detection of FGFR gene mutations in the tumor tissue and urine of patients
Study: NCT05349409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811 for Injection: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib Capsule
Description: Fluzoparib Capsule: Given PO.
Study: NCT06362330

Intervention type: OTHER
Intervention: magnetic resonance imaging
Description: Patients of bladder cancer underwent multiparameter magnetic resonance imaging before surgery

Intervention type: OTHER
Intervention: magnetic resonance imaging
Description: Patients of bladder cancer underwent multiparameter magnetic resonance imaging before surgery
Study: NCT05091697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent treatment VIRTUAL FIBROWALK + TAU
Description: To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
Study: NCT06801418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Specified dose on specified days
Study: NCT06429436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VENDY
Description: At least 1 machine (vending machine like a snack machine or a machine like a newspaper kiosk) will be placed in the respective community served by the participating organizations. Any person in the community can get naloxone from the machine. The vending machine will require a code that will be placed on the machine for anyone to use. The kiosks are a box that you simply pull open and naloxone can be obtained. Naloxone kits will be provided for free as part of the current naloxone distribution program within each respective organization.
Study: NCT06801613

Intervention type: OTHER
Intervention: Intervention Group
Description: Group/Cohort Description: Participants with Upper Cross Syndrome (UCS) who undergo the prescribed exercise or treatment protocol.
Study: NCT06801379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Melatonin (100 μg)
Description: An orally inhaled formulation of melatonin delivered by pressurised metered dose inhaler (pMDI) to be taken before bedtime. The pMDI will deliver a total of 100 μg of inhaled melatonin (2 x 50 μg/actuation). The investigational product is produced under Good Manufacturing Practice by Ab Initio Pharma Pty Ltd, a GMP certified manufacturer of pharmaceutical products.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Melatonin (4 mg)
Description: Two orally ingested tablets each containing 2 mg of melatonin (4 mg total) to be taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
Study: NCT04549155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
Study: NCT06800703

Intervention type: BEHAVIORAL
Intervention: follow up interviews for 12 months to determine opioid use
Description: Follow-up
Study: NCT06800664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation plan
Description: Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Providers in the control group will not receive ISS support
Study: NCT05139121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-100A-01
Description: Transdermal contraceptive delivery system
Study: NCT06801002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBZ-001
Description: JBZ-001 Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBZ-001
Description: JBZ-001 Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBZ-001
Description: JBZ-001 Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBZ-001
Description: JBZ-001 Oral Capsule
Study: NCT05091697

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent treatment VIRTUAL FIBROWALK + TAU
Description: To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
Study: NCT06010758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listerine Experimental Mouthwash
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
Study: NCT04693897

Intervention type: DRUG
Intervention: Solifenacin Succinate 5 MG
Description: Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
Study: NCT06587919

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: EEG-based neurofeedback, administered with the Neuroguide software.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback
Description: EEG-based neurofeedback, administered with the Neuroguide software.
Study: NCT05147324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPlan - Individualized Planned Eating Pattern
Description: Sessions involve a structured behavior change counseling module derived from FLEX (NCT01286350), DASH-4-Teens (NCT00585832), and a Social Cognitive Theory and Transtheoretical Model informed conceptual framework, which uses education, motivation and self-efficacy enhancement, goal setting, and problem-solving skills training to initiate and sustain eating pattern adherence. Sessions support incremental progress towards meeting all five eating behavior goals by helping youth develop action plans, troubleshoot barriers to adherence, and refine action plans to improve adherence. Youth log in MyFitnessPal at least three days per week. Logs are used to assess and troubleshoot adherence, support youth in developing and refining action plans, and reward youth with points. Incentives are allocated using a point scheme designed to promote logging and goal achievement. Formal adjustment of the eating pattern is based on adherence according to logs and youth/guardian acceptability.
Study: NCT06601218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral cannabis low THC
Description: 4 months daily dosing with oral cannabis low THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 4 months of daily dosing with oral placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral cannabis high THC
Description: 4 months of daily dosing with oral cannabis with high THC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral cannabis THC/CBD
Description: 4 months of daily dosing with oral cannabis with THC and CBD
Study: NCT04995588

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: Unique blood draw of 45mL for all the participants
Study: NCT06596564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: choice architecture
Description: Display the sugar content of the drink on the platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: choice architecture
Description: Showing the various harms that can come from long-term excessive consumption of sugary beverages on the platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: choice architecture
Description: The platform shows the information that the majority of their peers have chosen mineral water.
Study: NCT06207604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open sinus lifting without bone grafting and simultaneous implant placement
Description: no bone graft will be used after open sinus lifting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open sinus lifting with bone grafting and simultaneous implant placement
Description: bone graft will be packed palatally after open sinus elevation and before implant placement, then implant placement will took place followed by packing of bone grafts
Study: NCT06662968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lollipop group
Description: In the Lollipop group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were given lollipops for sucking without chewing after waking up.Throughout the entire sucking process, we continuously monitor vital signs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: In the Control group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were received routine nursing treatment.
Study: NCT06612840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-077
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT04865172

Intervention type: OTHER
Intervention: Remote collection of passive and active data for 28 consecutive days
Description: Passive sensor data: collected continuously for 28 days, from a multi-sensor wearable bracelet worn by each member of the dyad; Active questionnaire data: collected once a week during the four weeks of monitoring (and at the end of the 28 days for patient-caregiver dyads), from questionnaires filled by one partner of the dyad (for patient-caregiver dyads, this will be the caregiver) using a smartphone application.

Intervention type: OTHER
Intervention: Remote collection of passive and active data for 28 consecutive days
Description: Passive sensor data: collected continuously for 28 days, from a multi-sensor wearable bracelet worn by each member of the dyad; Active questionnaire data: collected once a week during the four weeks of monitoring (and at the end of the 28 days for patient-caregiver dyads), from questionnaires filled by one partner of the dyad (for patient-caregiver dyads, this will be the caregiver) using a smartphone application.

Intervention type: OTHER
Intervention: Remote collection of passive and active data for 28 consecutive days
Description: Passive sensor data: collected continuously for 28 days, from a multi-sensor wearable bracelet worn by each member of the dyad; Active questionnaire data: collected once a week during the four weeks of monitoring (and at the end of the 28 days for patient-caregiver dyads), from questionnaires filled by one partner of the dyad (for patient-caregiver dyads, this will be the caregiver) using a smartphone application.
Study: NCT06603623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-2100
Description: BHV-2100 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-2100
Description: BHV-2100 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT06668623

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reiki Group
Description: Remote Reiki application will be performed once a day for 20 minutes for four days by a researcher who has received second level training. No changes will be made to the standard treatment plan of the patients during the application.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Reiki Group
Description: In the placebo group, the Sham Reiki group will receive remote Reiki application in accordance with the application protocol by a nurse who is not a Reiki practitioner trained by the researcher and has not received any previous training.
Study: NCT06010758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.

Intervention type: DRUG
Group type: OTHER
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listerine Total Care Zero
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint Zero
Description: After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash twice a day, morning and night.
Study: NCT06678269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: The dose escalation portion of the study, a 3+3 design will be used. Once the MTD of Abemaciclib is reached, the phase Ib expansion portion will enroll up to 10 additional patients also requiring palliation to bone metastases